Staff Reports
We are closer than we have been in decades to new ways to treat Alzheimer’s. Scientists have a promising pill called LM11A-31 that may protect brain cells and keep the mind working. But good science can die in the laboratory if it never gets the money to finish the big trials. That gap—the biotech “valley of death”—is the real story here, and President Donald Trump can step in and make a difference.
LM11A-31: A different approach to Alzheimer’s
Most recent Alzheimer’s efforts chased amyloid plaques. That work was important, but it did not cure the disease. LM11A-31 aims at something else: synaptic resilience. In plain terms, it tries to keep the brain’s wiring strong so people remember names, faces and conversations longer. Early tests showed the pill is safe and may help preserve those connections. It is taken by mouth, not by infusion, and so far has not produced the brain swelling and bleeding seen with some other treatments.
The real roadblock is money—the “valley of death”
Phase III trials are the expensive finish line. They can cost hundreds of millions of dollars. Companies with a good drug can still fail because they cannot raise that final cash. That funding gap is not about science; it is about money and risk. We cannot let promising treatments stall because investors are afraid of losing their shirts. If LM11A-31 can really protect memory across more patients, it deserves a chance to prove it in large Phase III trials.
Here’s where President Donald Trump should act. He proved with past programs that government can move fast when it chooses. A targeted federal program to share risk—public-private partnerships, matching funds, or a mission-style push like the COVID vaccine effort—would get drugs across the valley of death. Conservatives should not reflexively fear federal spending here. This is smart investment, not a blank check: money that helps finish trials can lead to an approved drug, lower long-term care costs, and less burden on families and taxpayers down the road.
If Washington wants to help Americans and score a real win for patients and families, it should back proven science that needs a push. LM11A-31 and other brain-protecting therapies are worth that push. Call it common sense underwriting: we fund the last mile so the medicine can reach people. The alternative is letting bureaucracy and fear of risk keep new treatments on the shelf while families pay the price. That would be tragic—and frankly, unforgivable.
